{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:14:50Z","timestamp":1790388890308,"version":"4.1.0"},"reference-count":48,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2017.00098","type":"journal-article","created":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T04:01:25Z","timestamp":1495166485000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival"],"prefix":"10.3389","volume":"7","author":[{"given":"Ana Bel\u00e9n","family":"Herrero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma Carmen","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12185-013-1291-2","article-title":"Molecular pathogenesis of multiple myeloma: basic and clinical updates","volume":"97","author":"Chesi","year":"2013","journal-title":"Int J Hematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.blre.2015.06.001","article-title":"Treatment for patients with newly diagnosed multiple myeloma in 2015","volume":"29","author":"Mateos","year":"2015","journal-title":"Blood Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1182\/blood-2012-05-432203","article-title":"Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma","volume":"121","author":"Bergsagel","year":"2013","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1182\/blood-2007-05-089193","article-title":"Dysfunctional homologous recombination mediates genomic instability and progression in myeloma","volume":"113","author":"Shammas","year":"2009","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/leu.2011.94","article-title":"Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX","volume":"25","author":"Walters","year":"2011","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0121581","DOI":"10.1371\/journal.pone.0121581","article-title":"Deregulation of DNA double-strand break repair in multiple myeloma: implications for genome stability","volume":"10","author":"Herrero","year":"2015","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1158\/2159-8290.CD-14-0943","article-title":"Synthetic lethal approaches exploiting DNA damage in aggressive myeloma","volume":"5","author":"Cottini","year":"2015","journal-title":"Cancer Discov"},{"key":"B9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA damage response: making it safe to play with knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.yexcr.2014.09.030","article-title":"DNA replication stress: causes, resolution and disease","volume":"329","author":"Mazouzi","year":"2014","journal-title":"Exp Cell Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/nrm2852","article-title":"Maintaining genome stability at the replication fork","volume":"11","author":"Branzei","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1126\/science.282.5395.1893","article-title":"Linkage of ATM to cell cycle regulation by the Chk2 protein kinase","volume":"282","author":"Matsuoka","year":"1998","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrm3546","article-title":"The ATM protein kinase: regulating the cellular response to genotoxic stress, and more","volume":"14","author":"Shiloh","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1093\/nar\/gkv160","article-title":"Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation","volume":"43","author":"Bakr","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrm2351","article-title":"Regulation of DNA repair throughout the cell cycle","volume":"9","author":"Branzei","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.dnarep.2010.09.013","article-title":"The influence of heterochromatin on DNA double strand break repair: getting the strong, silent type to relax","volume":"9","author":"Goodarzi","year":"2010","journal-title":"DNA Repair (Amst)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.dnarep.2007.02.006","article-title":"DNA double-strand break repair: from mechanistic understanding to cancer treatment","volume":"6","author":"Helleday","year":"2007","journal-title":"DNA Repair (Amst)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2041-9414-3-9","article-title":"Pathway choice in DNA double strand break repair: observations of a balancing act","volume":"3","author":"Brandsma","year":"2012","journal-title":"Genome Integr"},{"key":"B19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev-genet-110410-132435","article-title":"Double-strand break end resection and repair pathway choice","volume":"45","author":"Symington","year":"2011","journal-title":"Annu Rev Genet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nrc3399","article-title":"DNA repair dysregulation from cancer driver to therapeutic target","volume":"12","author":"Curtin","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pharmthera.2016.02.003","article-title":"DNA repair targeted therapy: the past or future of cancer treatment?","volume":"160","author":"Gavande","year":"2016","journal-title":"Pharmacol Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.dnarep.2008.06.018","article-title":"Comparison of nonhomologous end joining and homologous recombination in human cells","volume":"7","author":"Mao","year":"2008","journal-title":"DNA Repair (Amst)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat Chem Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"10389","DOI":"10.1073\/pnas.190030497","article-title":"Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro","volume":"97","author":"Matsuoka","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B25","doi-asserted-by":"publisher","first-page":"49599","DOI":"10.1074\/jbc.M408353200","article-title":"Claspin and the activated form of ATR-ATRIP collaborate in the activation of Chk1","volume":"279","author":"Kumagai","year":"2004","journal-title":"J Biol Chem"},{"key":"B26","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1535-6108(03)00110-7","article-title":"Chk1 and Chk2 kinases in checkpoint control and cancer","volume":"3","author":"Bartek","year":"2003","journal-title":"Cancer Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1128\/MCB.16.8.4414","article-title":"A double-strand break within a yeast artificial chromosome (YAC) containing human DNA can result in YAC loss, deletion or cell lethality","volume":"16","author":"Bennett","year":"1996","journal-title":"Mol Cell Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1101\/gad.214080.113","article-title":"ATR phosphorylates SMARCAL1 to prevent replication fork collapse","volume":"27","author":"Couch","year":"2013","journal-title":"Genes Dev"},{"key":"B29","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.cell.2013.10.049","article-title":"Naked replication forks break apRPArt","volume":"155","author":"Fernandez-Capetillo","year":"2013","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nchembio.63","article-title":"A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex","volume":"4","author":"Dupre","year":"2008","journal-title":"Nat Chem Biol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1016\/j.bmcl.2004.09.060","article-title":"Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries","volume":"14","author":"Leahy","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"B32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.molcel.2013.11.003","article-title":"DNA double-strand break repair pathway choice is directed by distinct MRE11 nuclease activities","volume":"53","author":"Shibata","year":"2014","journal-title":"Mol Cell"},{"key":"B33","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1021\/cb100428c","article-title":"Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening","volume":"6","author":"Huang","year":"2011","journal-title":"ACS Chem Biol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.molonc.2011.07.002","article-title":"Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs","volume":"5","author":"Toledo","year":"2011","journal-title":"Mol Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/ncb1337","article-title":"ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks","volume":"8","author":"Jazayeri","year":"2006","journal-title":"Nat Cell Biol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"9346","DOI":"10.1074\/jbc.M513265200","article-title":"Rapid activation of ATR by ionizing radiation requires ATM and Mre11","volume":"281","author":"Myers","year":"2006","journal-title":"J Biol Chem"},{"key":"B37","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1038\/sj.emboj.7601446","article-title":"ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling","volume":"25","author":"Stiff","year":"2006","journal-title":"EMBO J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1084\/jem.20051923","article-title":"ATM regulates ATR chromatin loading in response to DNA double-strand breaks","volume":"203","author":"Cuadrado","year":"2006","journal-title":"J Exp Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"17501","DOI":"10.1074\/jbc.M701770200","article-title":"Ataxia-telangiectasia mutated (ATM)-dependent activation of ATR occurs through phosphorylation of TopBP1 by ATM","volume":"282","author":"Yoo","year":"2007","journal-title":"J Biol Chem"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1038\/sj.onc.1210849","article-title":"Interplay between ATM and ATR in the regulation of common fragile site stability","volume":"27","author":"Ozeri-Galai","year":"2008","journal-title":"Oncogene"},{"key":"B41","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"25885","DOI":"10.18632\/oncotarget.8292","article-title":"Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair","volume":"7","author":"Lima","year":"2016","journal-title":"Oncotarget"},{"key":"B43","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.molcel.2012.11.020","article-title":"Activation of DSB processing requires phosphorylation of CtIP by ATR","volume":"49","author":"Peterson","year":"2013","journal-title":"Mol Cell"},{"key":"B44","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.tips.2011.02.014","article-title":"Anticancer therapy with checkpoint inhibitors: what, where and when?","volume":"32","author":"Garrett","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/cas.12366","article-title":"Targeting DNA damage response in cancer therapy","volume":"105","author":"Hosoya","year":"2014","journal-title":"Cancer Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"7816","DOI":"10.1038\/sj.onc.1210879","article-title":"Targeted cancer therapies based on the inhibition of DNA strand break repair","volume":"26","author":"O\u2019Connor","year":"2007","journal-title":"Oncogene"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-11-0949","article-title":"The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells","volume":"11","author":"Landau","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3389\/fonc.2014.00289","article-title":"A small-molecule inhibitor of RAD51 reduces homologous recombination and sensitizes multiple myeloma cells to doxorubicin","volume":"4","author":"Alagpulinsa","year":"2014","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2017.00098\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T04:01:30Z","timestamp":1495166490000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2017.00098\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,19]]},"references-count":48,"alternative-id":["10.3389\/fonc.2017.00098"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2017.00098","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,19]]},"article-number":"98"}}